Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
What adjuvant therapy would you offer a TNBC patient with residual disease after receiving the neoadjuvant KEYNOTE-522 regimen?
Answer from: Medical Oncologist at Academic Institution
Safety is pembro and cape was provided in phase I trials. Risk and benefit weighing is important when discussing with patients.
Sign in or Register to read more
12421
Related Questions
Would you discontinue or dose-reduce Tamoxifen in a patient that developed hepatic steatosis?
How would you approach the treatment of low grade, stage IA, triple negative apocrine adenocarcinoma of the breast in a female patient in her 70s?
Would you offer adjuvant chemotherapy for triple negative invasive papillary carcinoma of breast?
Would you offer adjuvant endocrine therapy for a postmenopausal female with stage III triple positive multicentric breast cancer (DCIS and invasive ductal carcinoma) s/p neoadjuvant TCHP followed by bilateral mastectomy with no residual disease?
What are your top takeaways in Medical Oncology from SABCS 2024?
Would you recommend adjuvant endocrine therapy in combination with immunotherapy for triple negative metaplastic breast cancer with residual disease that is ER strongly positive?
In a patient with BRCA2 mutation and contralateral axillary recurrence of ER+ IDC with an ESR1 CCDC170 fusion on NGS testing, would you use standard adjuvant AI therapy or consider adjuvant SERD therapy (fulvestrant/elacestrant)?
How do you manage a patient with early stage HER2+ breast cancer patient who progressed on mastectomy after completing neoadjuvant TCHP?
What is your preferred method of surveillance after mastectomy?
What adjuvant therapy would you recommend for a premenopausal woman with low ER+/PR+ (1-10%) HER2- pT1cN0 metaplastic breast cancer?